Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Genmab A/S announced it has completed enrollment of 273 patients in the zalutumumab pivotal Phase III study in refractory head and neck cancer. Genmab expects to report final results from the study by the end of 2009.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address